6.3%; HR, 1.35; 95% CI, 1.00–1.84).
After 10 years of follow-up, there was no difference in DFS between the two arms (73.6% for the 2-year course vs.
73.9% for the 5-year course [HR, 0.99; 95% CI, 0.85–1.15;P= .90]).
In addition, there was no difference in OS, time to second primary cancer, and time to contralateral breast cancer between the arms.[87][Level of evidence B1] There was a trend toward more fractures in the 5-year arm (4.7% vs.
6.3%; HR, 1.35; 95% CI, 1.00–1.84).
An open-label trial in Japan included 1,697 patients who had received either (1) 5 years of anastrozole or (2) 2 to 3 years of tamoxifen, followed by 2 to 3 years of anastrozole.